|
|
Volumn 9, Issue 4, 2008, Pages 320-321
|
|
Rituximab for follicular non-Hodgkin lymphoma.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
MONOCLONAL ANTIBODY;
RITUXIMAB;
CLINICAL TRIAL;
EVALUATION;
FEMALE;
FOLLICULAR LYMPHOMA;
HOSPITALIZATION;
HUMAN;
MALE;
MEDICAL SOCIETY;
MORTALITY;
NOTE;
PROGNOSIS;
REMISSION;
SENSITIVITY AND SPECIFICITY;
SURVIVAL;
TREATMENT OUTCOME;
UNITED KINGDOM;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CLINICAL TRIALS AS TOPIC;
EVALUATION STUDIES AS TOPIC;
FEMALE;
GREAT BRITAIN;
HUMANS;
LYMPHOMA, FOLLICULAR;
MALE;
PROGNOSIS;
REMISSION INDUCTION;
SENSITIVITY AND SPECIFICITY;
SEVERITY OF ILLNESS INDEX;
SOCIETIES, MEDICAL;
SURVIVAL ANALYSIS;
TREATMENT OUTCOME;
MLCS;
MLOWN;
|
|
EID: 41049090274
PISSN: None
EISSN: 14745488
Source Type: Journal
DOI: 10.1016/s1470-2045(08)70036-6 Document Type: Note |
|
Times cited : (5)
|
|
References (0)
|
